Immunocytology as a possible marker to identify patients who require prophylaxis.
Huland
H
H
Department of Urology, University, Steglitz, Berlin.
Schneider
A
A
Huland
E
E
Arndt
R
R
D000283:Administration, Intravesical; D000368:Aged; D000911:Antibodies, Monoclonal; D000951:Antigens, Neoplasm / Q000652:urine*; D014408:Biomarkers, Tumor / Q000652:urine*; D002295:Carcinoma, Transitional Cell / Q000188:drug therapy / Q000601:surgery / Q000652:urine*; D006801:Humans; D008875:Middle Aged; D016685:Mitomycin; D008937:Mitomycins / Q000627:therapeutic use; D015337:Multicenter Studies as Topic; D009364:Neoplasm Recurrence, Local / Q000517:prevention & control*; D011237:Predictive Value of Tests; D011446:Prospective Studies; D016032:Randomized Controlled Trials as Topic; D001749:Urinary Bladder Neoplasms / Q000188:drug therapy / Q000601:surgery / Q000652:urine*
D000911:Antibodies, Monoclonal; D000951:Antigens, Neoplasm; D014408:Biomarkers, Tumor; D008937:Mitomycins; D016685:Mitomycin